Welcome to our dedicated page for Immunoprecise SEC filings (Ticker: IPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd. (IPA), files as a foreign private issuer and its SEC reports document operating results, platform development, capital structure, governance matters, and risk disclosures. Form 6-K reports furnish earnings releases and business updates for the Bio-Native AI drug-discovery business, including LensAI™, HYFT® technology, biologics services, B Cell Llama™ nanobody discovery, immunogenicity screening, and vaccine-target research.
The filing record also captures corporate-status changes tied to the MindWalk rebrand and Nasdaq ticker change, along with disclosures on issued capital, share-based awards, lease obligations, development costs, segment information, material agreements, and historical financial condition. These documents frame the company's transition from specialized wet-lab antibody services toward an integrated AI and laboratory platform model.